Portola Pharmaceuticals — Investor Presentation (September 2017)
31 slides from Portola Pharmaceuticals's investor presentation, Sep 11, 2017
Slide 1: Portola Pharmaceuticals September 2017
Portola Pharmaceuticals September 2017 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases you can identify these statements by forward-looking words, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate
Slide 3: Clinical Pipeline of Innovative Products in Areas of Highest Medical Need
Clinical Pipeline of Innovative Products in Areas of Highest Medical Need THROMBOSIS & HEMATOLOGY Pre-clinical PHASE 1 PHASE 2 PHASE 3 FDA/ EMA Review Oral, Factor Xa Inhibitor Prophylaxis for hospitalized acute medically ill patients at risk for VTE FXa inhibitor antidote/ reversal agent hospitaliz
Slide 4: Significant Regulatory Milestones & Upcoming Catalysts for Two Products
Significant Regulatory Milestones & Upcoming Catalysts for Two Products Timing Event June 23 APPROVED BY U.S. FDA Q4 2017 CHMP Opinion Q4 17 – Q1 18 U.S. Launch Planned Q1 2018 EMA Approval Expected Timing Event August 3 BLA Re-Submission Q1 2018 CHMP Opinion Feb 3, 2018 FDA PDUFA Q1 2018 EMA Approv
Slide 5: Betrixaban and Andexanet Alfa Target Multi-Billion Dollar Markets
Betrixaban and Andexanet Alfa Target Multi-Billion Dollar Markets Where No Drugs Approved/Limited Options $ BILLIONS Current & Projected DOAC sales worldwide* $17B* $3-4B >$2B >$5B & addressable market Sources: *Evaluate Pharma June 7, 2017; Portola estimates Note: SPAF = stroke prevention in patien
Slide 6: Urgent Need to Address Preventable Deaths from VTE
>24 Million Acute medical patients indicated for VTE prevention (US+EU5+Japan) >1 Million will suffer a blood clot within 35 days 150,000 estimated to survive condition but die of VTE every year 41 year old, acute medically ill patient Urgent Need to Address Preventable Deaths from VTE Acute Medical
Slide 7: Betrixaban's Unique Properties to Reduce VTE without Increasing Major Bleeding
Betrixaban’s Unique Properties to Reduce VTE without Increasing the Rate of Major Bleeding Once-daily half life ✓ Lowest renal clearance ✓ Not metabolized by CYP3A4 (Commonly used CYP3A4 inhibitors – e.g., clarithromycin, erythromycin, HIV protease inhibitors, fluconazole, itraconazole) ✓ BETRIXABAN
Slide 8: APEX Study Design: Hospital & Extended Duration Betrixaban vs Enoxaparin
APEX Study Design: Hospital & Extended Duration Betrixaban Compared to Standard Duration Enoxaparin Enrollment: 7,513 patients Primary End Point: Day 35 - 42 Day 65 - 70 Hospitalization Day 10 + 4 R Enoxaparin Betrixaban Placebo Betrixaban 1:1 randomization Age ≥75 D-dimer Multiple risk factors Stra
Slide 9: FDA Label: Efficacy Analyses Based on mITT Population
FDA Label: Efficacy Analyses Were Performed Based on the Modified Intent-to-Treat (mITT) Population APEX mITT population: all patients who had taken at least one dose of study drug and had follow-up assessment of at least one or more primary or secondary efficacy outcome components. Largest APEX pre
Slide 10: Primary Efficacy Endpoint (mITT population 80mg and 40mg doses)
Primary Efficacy Endpoint (mITT population 80mg and 40mg doses) 223/3720 165/3721 mITT=Modified intent-to-treat; RRR=relative risk reduction BEVYXXA [Package Insert], Portola Pharmaceuticals, Inc.; ARR = absolute risk reduction; NNT = number needed to treat to prevent one event ¢ Enoxaparin/Placebo
Slide 11: Primary Efficacy Endpoint (mITT population 80mg dose)
mITT= Modified intent-to-treat; RRR=relative risk reduction BEVYXXA [Package Insert], Portola Pharmaceuticals, Inc Primary Efficacy Endpoint (mITT population 80mg dose) 180/2926 120/2878 ¢ Enoxaparin/Placebo ¢ Betrixaban 80 mg Primary Composite Endpoint: VTE DAY 42 OVERALL POPULATION RRR=31.7% ARR=2
Slide 12: Time to Symptomatic VTE Event
Time to Symptomatic VTE Event (mITT population 80mg and 40mg doses) EFFICACY (EXPLORATORY ENDPOINT) COMPOSITE OF SYMPTOMATIC PROXIMAL OR DISTAL DVT, NON-FATAL PE, OR VTE-RELATED DEATH HR=hazard ratio Data on File; Portola Pharmaceuticals, Inc.; PE = pulmonary embolism; CI = confidence interval; HR =
Slide 13: Major Bleeding (Safety Population)
Major Bleeding (Safety Population 80mg and 40mg doses) RR=1.19 (95% CI 0.67-2.12) P=0.55 Event Rate (%) SAFETY (PRIMARY ENDPOINT) MAJOR BLEEDING TYPES OF MAJOR BLEEDING Cohen AT et al. N Engl J Med. 2016;375:534-44.; RR risk reduction; ICH = intracranial hemorrhage; *Other major bleeding includes he
Slide 14: Clinically Relevant Non-Major Bleeding
Clinically Relevant Non-Major Bleeding (Safety Population 80mg and 40mg doses) Event Rate (%) RR=2.39 (95% CI 1.64-3.49) P<0.001 BEVYXXA [Package Insert], Portola Pharmaceuticals, Inc; CRNM = clinically relevant non-major bleed; 38/3716 91/3716 CRNM bleeding was defined as overt bleeding not meeting
Slide 15: Time to Ischemic Stroke in Patients With Ischemic Stroke or CHF
Time to Ischemic Stroke in Patients With Ischemic Stroke or CHF as Index Event (Post hoc, 80mg and 40mg doses) Gibson CM et al. Circulation. 2017;135(7):648-655; CHF = congestive heart failure; NOAC = novel oral anticoagulant; 0.0 0.5 1.0 Probability of Ischemic Stroke (%) 0 5 10 15 20 25 30 35 40 4
Slide 16: VTE-related Mortality and Re-hospitalizations (Post hoc)
VTE-related Mortality and Re-hospitalizations (Post hoc) (mITT Population 80mg dose) Publication Pending - Data on file PERFUSE Study Group 1.25 1.50 1.00 0.75 0.50 0.25 0.00 0 77 70 10 THROUGH END OF TRIAL ARR=0.79 HR=0.37 (0.20-0.70) NNT=127 1.25% Time (days) 0.46% Probability of Rehospitalization
Slide 17: Fatal or Irreversible Outcomes Net Clinical Benefit
Fatal or Irreversible Outcomes Net Clinical Benefit (mITT population 80mg and 40mg doses) Non-hemorrhage cardiopulmonary death + Non-fatal PE + MI + ischemic stroke + Fatal bleeding + ICH *End of Trial defined as final follow-up visit (30 + 5 days after Visit 3) Through End of Trial* HR = 0.70 (95%
Slide 18: Budget Impact Model: Bevyxxa 80mg Highly Cost Effective
Budget Impact Model: Bevyxxa 80mg Highly Cost Effective with Robust Clinical Outcomes and Short Course of Therapy Absolute Reduction in Clinical Events (e.g., VTE, CV Death, ICH, Bleed, MI, Stroke) Cost by Type of Clinical Event Cost Savings Model Flow x = - Net Drug & Administration Costs Highlight
Slide 19: Cost per Event Saved Model: Compares Favorably to Other Cardiovascular Products
Cost per Event Saved Model: Compares Favorably to Other Cardiovascular Products 0.9% 114 Chronic, 8-10+ yrs $4,400/ yr $500,000 1.0% 100 Chronic, 8-10+ yrs $4,500/ yr $450,000 0.5% 200 Chronic, 8-10+ yrs $10,000/ yr ~$2,000,000 1.8% 56 40 days ~$600 $33,600 *Events include annualized addition of CV
Slide 20: Betrixaban Has Potential to Expand $2.7B Addressable Market to $3-4B
Betrixaban Has Potential to Expand $2.7B Addressable Market to $3-4B in G7 2025 2021 2015 28.4 26.6 24.0 Acute Medical Hospital Stays (millions in US, EU5, Japan) Injectables 24M patients 6 days of therapy 55% adoption ~$2.7B peak market Betrixaban 16M patients 35 days of therapy Parity pricing to o
Slide 21: Bleeding in Factor Xa Inhibitor Patients Is a Major and Growing Cause of Hospital Admissions
Bleeding in Factor Xa Inhibitor Patients Is A Major and Growing Cause of Hospital Admissions, Morbidity and Death Expanding ICH in a Xarelto patient ~200,000 2016 oral FXa inhibitors hospital bleeding admissions in US, EU5 & Japan, 84,000 urgent surgeries.1 Potential 30,000 additional bleeding admis
Slide 22: Andexanet Alfa Has Potential to Be the First and Only Universal FXa Antidote
Andexanet Alfa Has Potential to be the First and Only Antidote For Universal Fxa Inhibitor Reversal Andexanet alfa is an investigational product that has not yet been approved for use Attractive for hospital setting Immediate onset Sustained infusion reversal Short half-life Only agent to reduce ant
Slide 23: Phase 3b/4 Confirmatory Study in Patients with Acute Major Bleeding
Phase 3b/4 Confirmatory Study in Patients with Acute Major Bleeding Up to 350 pts with life threatening bleeding Co-primary efficacy endpoints Andexanet alfa 1. Anti-Xa 2. Hemostasis 12hrs 30 day safety follow up Andexanet IV bolus and 2 hour infusion >160 patients currently enrolled in US and EU Hi
Slide 24: Interim Results: Andexanet Alfa Decreases Apixaban Anti-FXa Activity
Interim Results: Andexanet Alfa Rapidly and Significantly Decreases Apixaban Anti-FXa Activity Apixaban: Bolus +Infusion Anti-FXa [median, 25th, 75th percentiles, N=20] Time since Bolus (hrs) Anti-Factor Xa (ng/ml) Apixaban (N=20) 0 50 100 150 200 0.0 0.2 0.4 0.6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Slide 25: 80% Adjudicated Excellent/Good Clinical Hemostasis
80% Adjudicated Excellent/Good Clinical Hemostasis Interim Results Drug Rivaroxaban 26 81 (61/93) Apixaban 20 75 (51-91) Enoxaparin 1 100 Site of bleeding Gastrointestinal 25 84 (64-96) Intracranial 20 80 (56-94) Other 2 0 Andexanet dose Low 42 76 (61-88) High 5 100 (48-100) Anti-factor Xa <75 ng/ml
Slide 26: We Intend to Target the Most Severe and Life-threatening Bleeds
We Intend to Target the Most Severe and Life-threatening Bleeds and Expand Based on Label and Supply Sources: Patel al. 2011. N Engl J Med. 2011 Sep 8;365(10):883-91; Piccini JP, et al., Eur Heart J. 2014 Jul 21;35(28):1873-80; Granger CB, Alexander JH, McMurray JJ, et al. N Engl J Med. 2011 Sep 15;
Slide 27: Cerdulatinib: A New SYK-JAK Option for Resistant or Relapsed Hematological Cancers
Cerdulatinib: A New SYK-JAK Option for Resistant or Relapsed Hematological Cancers and Other Diseases Pharmacyclics ImbruvicaTM Gilead Zydelig Infinity IPI-145 Incyte Jakafi® CERDULATINIB PI3K B-cell Receptor Pro-Inflammatory Tumor Environment Cytokines IL-2, IL-4, IL-6, IL-10, TNFα Tumor Derived Cy
Slide 28: Cerdulatinib: Best Overall Response in Ongoing Phase 2 Study
Cerdulatinib: Best overall response in ongoing phase 2 study Median time to response – 2 months *Includes 4 PRs with lymphocytosis. 7 additional patients on drug – too early for evaluation. Presented at ICML and EHA 2017 Response CLL/SLL (n = 18) FL (n = 9) Other NHL (n =12) PTCL (n = 1) Total (n =
Slide 29: Cerdulatinib Adverse Events by Initial Dose
Cerdulatinib Adverse Events by Initial Dose Table does not include events deemed “unrelated” to study treatment. Therapy-related adverse events occurring in ³3 patients Adverse event, n (%) 35 mg BID (n = 17) 30 mg BID (n = 30) G3/G4 G5 G3/G4 G5 Neutropenia/neutrophil count decreased 4 (24) 0 2 (7)
Slide 30: Capitalized to Fund Projected Development Milestones
Andexxa Bevyxxa 2016 2017 Capitalized to Fund Projected Development Milestones $269.7M Cash, Cash Equivalents & Investments as of 6/30/17 Phase 4 Ongoing 2017 2018 BLA Resubmitted EMA Approval Approved6/23/17 CHMP Opinion EMA Approval CHMP Opinion EMA Supplemental Approval (Gen 2) Cerdulatinib Initi
Slide 31: NASDAQ: PTLA
NASDAQ: PTLA
Portola Pharmaceuticals — Investor Presentation (September 2017) on 6ix